Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries

The increasing availability of biosimilar medicines in Middle Eastern regions may provide an opportunity to increase the number of rheumatology patients who have access to traditionally more expensive biologic medicines. However, as well as a lack of real-world data on the use of biosimilar medicine...

Descripción completa

Detalles Bibliográficos
Autores principales: El Zorkany, Bassel, Al Ani, Nizar, Al Emadi, Samar, Al Saleh, Jamal, Uthman, Imad, El Dershaby, Yasser, Mounir, Mohamed, Al Moallim, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913383/
https://www.ncbi.nlm.nih.gov/pubmed/29411181
http://dx.doi.org/10.1007/s10067-018-3982-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913383/
https://www.ncbi.nlm.nih.gov/pubmed/29411181
http://dx.doi.org/10.1007/s10067-018-3982-9

Ejemplares similares